Skip to main content
Clinical Trials/CTRI/2024/02/063292
CTRI/2024/02/063292
Not Yet Recruiting
Phase 3

Assessment of Effectiveness of Empagliflozin in the Management of Anemia in Type 2 Diabetes Patients with Early Stage of Chronic Kidney Disease- A Prospective Randomised COntrol Study - NI

SRM Insitute of Science and Technology0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
SRM Insitute of Science and Technology
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
SRM Insitute of Science and Technology

Eligibility Criteria

Inclusion Criteria

  • Estimated glomerular filtration rate 45 to 90 ml per minute .
  • Diabetic patients HbA1C greater than 6\.5 percent
  • Patients with haemoglobin less than 13\.0 g per dL in males.
  • Haemoglobin less than 12\.0 g per dL in females.

Exclusion Criteria

  • End Stage Renal Disease patients Stage 4
  • Patients with hereditary iron metabolism disorders.
  • Patients with Type 1 Diabetes mellitus.
  • Patients with pre\-existing Urinary tract or Genital infections and patients who develop this complication during the study.
  • Patient with pyelonephritis.
  • Patients already taking diuretics.
  • Pregnant and Lactating women.
  • Treatment with any other investigational drug within the previous 30 days of inclusion in the study.
  • Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements.
  • Difficulty in Socio Culture Communication.

Outcomes

Primary Outcomes

Not specified

Similar Trials